Contact Us 联系我们
Contact Us 联系我们
Contact Us 联系我们

Investors

Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements



DateTitle
21/06/2018Bisantrene approval in UK for supply as unlicensed medicineDownload
20/06/2018Results of General MeetingDownload
20/06/2018Trading HaltDownload
18/06/2018Appendix 3Y - Peter MolloyDownload
05/06/2018RAC cancer drug success in AML reported by French doctorsDownload
04/06/2018Expiry of Unlisted OptionsDownload
17/05/2018Notice of General Meeting/Proxy FormDownload
15/05/2018Race appoints Oncologist to head Medical AffairsDownload
15/05/2018Race executes agreement for Bisantrene clinical trialDownload
07/05/2018Interview with Dr John CullityDownload
1  2  3  4  5  6  7  8  9  10  11  

ASX: RAC

Price

Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2018 Race Oncology. Website By Multiplier